These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28388242)

  • 1. Therapeutic targeting of isocitrate dehydrogenase mutant AML.
    Boddu P; Borthakur G
    Expert Opin Investig Drugs; 2017 May; 26(5):525-530. PubMed ID: 28388242
    [No Abstract]   [Full Text] [Related]  

  • 2. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML.
    DiNardo CD; Stein EM
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):769-772. PubMed ID: 30416011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120.
    Birendra KC; DiNardo CD
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):460-5. PubMed ID: 27245312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.
    Upadhyay VA; Brunner AM; Fathi AT
    Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects.
    Kowalczyk A; Zarychta J; Lejman M; Latoch E; Zawitkowska J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.
    Becker JS; Fathi AT
    Curr Cancer Drug Targets; 2020; 20(7):490-500. PubMed ID: 32329690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?
    Hauge M; Bruserud Ø; Hatfield KJ
    Eur J Haematol; 2016 Mar; 96(3):211-21. PubMed ID: 26465810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of mutant IDH1 in acute myeloid leukaemia.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638561
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting the
    Amaya ML; Pollyea DA
    Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
    Waitkus MS; Diplas BH; Yan H
    Cancer Cell; 2018 Aug; 34(2):186-195. PubMed ID: 29805076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enasidenib.
    Krämer A; Bochtler T
    Recent Results Cancer Res; 2018; 212():187-197. PubMed ID: 30069631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Research advances of IDH gene mutation and AML].
    Sun MD; Zheng YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1485-9. PubMed ID: 25338613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons for optimism in the therapy of acute leukemia.
    Rowe JM
    Best Pract Res Clin Haematol; 2015; 28(2-3):69-72. PubMed ID: 26590761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Therapeutics in Acute Myeloid Leukemia.
    DiNardo CD; Stone RM; Medeiros BC
    Am Soc Clin Oncol Educ Book; 2017; 37():495-503. PubMed ID: 28561688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia: An Evolving Treatment Landscape.
    Lachowiez C; DiNardo CD; Stein E
    Cancer J; 2022 Jan-Feb 01; 28(1):21-28. PubMed ID: 35072370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDH1 inhibitor shows promising early results.
    Cancer Discov; 2015 Jan; 5(1):4. PubMed ID: 25583779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.
    Ragon BK; DiNardo CD
    Curr Hematol Malig Rep; 2017 Dec; 12(6):537-546. PubMed ID: 29064021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.